586 related articles for article (PubMed ID: 17192343)
1. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
2. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.
Hadigan C; Meigs JB; Corcoran C; Rietschel P; Piecuch S; Basgoz N; Davis B; Sax P; Stanley T; Wilson PW; D'Agostino RB; Grinspoon S
Clin Infect Dis; 2001 Jan; 32(1):130-9. PubMed ID: 11118392
[TBL] [Abstract][Full Text] [Related]
3. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians.
Forouhi NG; Sattar N; McKeigue PM
Int J Obes Relat Metab Disord; 2001 Sep; 25(9):1327-31. PubMed ID: 11571595
[TBL] [Abstract][Full Text] [Related]
4. Higher prevalence of diabetes in hypertensive subjects with upper body fat distribution.
Escobedo-de-la-Peña J; Islas S; Lifshitz-Guinzberg A; Méndez JD; Revilla C; Vázquez-Estupiñán F
Rev Invest Clin; 1998; 50(1):5-12. PubMed ID: 9608783
[TBL] [Abstract][Full Text] [Related]
5. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine.
Thiébaut R; Daucourt V; Mercié P; Ekouévi DK; Malvy D; Morlat P; Dupon M; Neau D; Farbos S; Marimoutou C; Dabis F
Clin Infect Dis; 2000 Dec; 31(6):1482-7. PubMed ID: 11096016
[TBL] [Abstract][Full Text] [Related]
6. The fat redistribution syndrome in patients infected with HIV: measurements of body shape abnormalities.
Gerrior J; Kantaros J; Coakley E; Albrecht M; Wanke C
J Am Diet Assoc; 2001 Oct; 101(10):1175-80. PubMed ID: 11678488
[TBL] [Abstract][Full Text] [Related]
7. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
[TBL] [Abstract][Full Text] [Related]
8. [Abdominal obesity and coronary heart disease. Pathophysiology and clinical significance].
Hauner H
Herz; 1995 Feb; 20(1):47-55. PubMed ID: 7713476
[TBL] [Abstract][Full Text] [Related]
9. Effect of smoking on the prevalence of insulin resistance-associated cardiovascular risk factors among Finnish men in military service.
Tähtinen TM; Vanhala MJ; Oikarinen JA; Keinänen-Kiukaanniemi SM
J Cardiovasc Risk; 1998; 5(5-6):319-23. PubMed ID: 9920003
[TBL] [Abstract][Full Text] [Related]
10. The insulin resistance syndrome in Mexico. Prevalence and clinical characteristics: a population based study.
González Villalpando C; Stern MP; Haffner S; Arredondo Pérez B; Martínez Diaz S; Islas Andrade S
Arch Med Res; 1995; 26 Spec No():S9-15. PubMed ID: 8845665
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone and the metabolic syndrome.
Johannsson G; Bengtsson BA
J Endocrinol Invest; 1999; 22(5 Suppl):41-6. PubMed ID: 10442570
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.
Carr A; Samaras K; Thorisdottir A; Kaufmann GR; Chisholm DJ; Cooper DA
Lancet; 1999 Jun; 353(9170):2093-9. PubMed ID: 10382692
[TBL] [Abstract][Full Text] [Related]
13. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
Holstein A; Plaschke A; Egberts EH
Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
[TBL] [Abstract][Full Text] [Related]
14. Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome.
Hadigan C; Corcoran C; Piecuch S; Rodriguez W; Grinspoon S
J Clin Endocrinol Metab; 2000 Oct; 85(10):3544-50. PubMed ID: 11061499
[TBL] [Abstract][Full Text] [Related]
15. [Metabolic complications associated with use of protease inhibitors].
Mosnier-Pudar H
Ann Med Interne (Paris); 2000 Jun; 151(4):278-82. PubMed ID: 10922955
[TBL] [Abstract][Full Text] [Related]
16. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.
Rietschel P; Hadigan C; Corcoran C; Stanley T; Neubauer G; Gertner J; Grinspoon S
J Clin Endocrinol Metab; 2001 Feb; 86(2):504-10. PubMed ID: 11158000
[TBL] [Abstract][Full Text] [Related]
17. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Hadigan C; Meigs JB; Rabe J; D'Agostino RB; Wilson PW; Lipinska I; Tofler GH; Grinspoon SS;
J Clin Endocrinol Metab; 2001 Feb; 86(2):939-43. PubMed ID: 11158071
[TBL] [Abstract][Full Text] [Related]
18. Fat, sugar and drugs on the French Riviera.
Lands L
GMHC Treat Issues; 1999 Mar; 13(3):9-11. PubMed ID: 11366205
[TBL] [Abstract][Full Text] [Related]
19. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.
Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F
New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090
[TBL] [Abstract][Full Text] [Related]
20. Reversal of cachexia in patients treated with potent antiretroviral therapy.
Scevola D; Di Matteo A; Uberti F; Minoia G; Poletti F; Faga A
AIDS Read; 2000 Jun; 10(6):365-9, 371-5. PubMed ID: 10881368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
